- Details
- Description
-
Packaging Size112t/bottle
-
Strength150mg/t
-
CompositonDupert (Fulzerasib)
-
TreatmentNSCLC treatment in adults with the KRAS G12C mutation
-
FormTablet
-
Brand达伯特 (Dupert)
-
Quantity Unit150mg*112T/Box
-
ManufacturerInnovent Biopharmaceutical , china
About Fulzerasib
Fulzerasib is a novel, orally active, potent KRAS G12C inhibitor designed to effectively target the GTP/GDP exchange, an essential step in pathway activation, by modifying the cysteine residue of KRAS G12C protein covalently and irreversibly. Preclinical cysteine selectivity studies demonstrated high selectivity of fulzerasib towards G12C. Subsequently, fulzerasib effectively inhibits the downstream signal pathway to induce tumor cells' apoptosis and cell cycle arrest.
- Fulzerasib sold under the brand name 达伯特® (Dupert) in china.
RAS protein family can be divided into KRAS, HRAS and NRAS categories. KRAS mutation are detected in nearly 90% of pancreatic cancer, 30-40% of colon cancer, and 15-20% lung cancer patients. The occurrence of KRAS G12C mutation subset is more frequently observed than those with ALK, ROS1, RET and NTRK 1/2/3 mutations combined.
Recommended dose
The recommended dose of Fulzerasib is 600 mg orally twice a day (approximately 12 hours apart), taken on an empty stomach or after meals, and continued until disease progression or unacceptable toxicity occurs.
- Swallow the tablets whole. Do not chew, crush or split the tablets.
- It is recommended to take this product at the same time every day.
- If you miss a dose during medication, if it is more than 4 hours from the expected dose time, do not make up for it and resume medication at the next scheduled time.
- If vomiting occurs after taking Fulzerasib , do not take another dose.
- Resume medication at the next scheduled time.
